, 2017 of THB 72.28 million, decreased by THB 114.98 million or 269.26% comparing to the Year 2016 ended as of December 31 , 2016 which the realized net profit for THB 42.70 million, for the following
company and its subsidiaries financial statement for Year 2017 end as of December 31, 2017, which details are as following; Results Year 2017 Year 2016 Increase (Decrease) Million Baht Million Baht Million
ม์ากขึน้เมือ่ราคาหลักทรัพยต์ ่ากว่าราคาเสนอขาย และหากราคาหลักทรัพยส์งูกว่า ราคาเสนอขายอาจจะมปีรมิาณหลักทรัพยท์ีส่ามารถน ามาซือ้ขายไดม้ากขึน้” - In case an offering includes green shoe option, the following
subsidiary, please kindly find the following attachment. Please kindly be informed accordingly. Yours faithfully, Mr. Geza Emil Perlaki Managing Director For period ended 31 December 2019 MANAGEMENT DISCUSSION
85.65% of paid-up capital shares. Following this transaction, the Company has acquired a business which operate in the Biopharmaceutical products. 4) the purchase price Total amount of Baht 50 million 3
results of the Company and its subsidiary, please kindly find the following attachment. Please kindly be informed accordingly. Yours faithfully, Mr. Geza Emil Perlaki Managing Director For period ended 30
operating results of the Company and its subsidiary, please kindly find the following attachment. Please kindly be informed accordingly. Yours faithfully, Mr. Geza Emil Perlaki Managing Director For period
(Decrease) % 2019 2018 Revenues from sales and services 817.56 656.71 160.85 24.49% Gross profit from sales and services 181.55 125.50 56.05 44.66% Other income 4.85 6.10 (1.25) (20.49%) Selling expenses
information shall cover at least the following matters: 1.1 Vision, objectives, goals and strategies Provide as much information as deemed appropriate on the vision, objectives, goals and business strategies of